Melanoma Diagnostics

After reporting a 27 percent increase in its fiscal third quarter revenues, Myriad Genetics this week outlined three strategic directives for diversifying its revenue base, including growing sales of its existing tests in the US, launching new tests and companion diagnostics in a

In addition to a five-marker diagnostic test that the company plans to launch in the second half of 2011, Myriad is developing a second melanoma test that would gauge survival benefit.

Myriad will develop tests using genetic markers acquired from Melanoma Diagnostics.

Under the terms of the deal, Myriad will have commercialization rights to "all tests derived from the technology on a worldwide basis in exchange for upfront fees and contingent payments based upon the commercial success of the products."

360Dx reports that the US Centers for Medicare & Medicaid Services would cover next-generation sequencing-based cancer panel tests.

The Washington Post reports that a meteorologist is being considered as presidential science and technology advisor.

In PNAS this week: precision medicine strategy to screen for disease risk, genome evolution in Haemophilus influenzae, and more.

Researchers have developed a PCR-based assay to gauge whether manatees are present in waters.